PLEASANTON, Calif., July 30, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® prime Pre-analytical System to improve efficiency in molecular diagnostics ...
cobas 5800 is a new compact addition to the Roche molecular diagnostics portfolio that provides a scalable, high performance testing solution for labs of all sizes. Infectious diseases, such as HIV, ...
Roche launched a relatively more compact addition to its mainstay cobas molecular diagnostic lineup with instruments that aim to bring automated testing to laboratories of all sizes. Roche is ...
INDIANAPOLIS, March 23, 2016 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has submitted the Elecsys BRAHMS PCT (Procalcitonin) assay for Premarket Notification (510k) to the U.S ...
HERLEV, Denmark , May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT ...
Roche Diagnostics has launched its new molecular laboratory instrument, the cobas ® 5800 System, in the UK. Through improved automation the new system can help raise testing volumes, improve ...
PLEASANTON, Calif., March 30, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the FDA approval of a new pre-analytical instrument that provides an integrated primary tube ...
A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
INDIANAPOLIS, Sept. 13 /PRNewswire-FirstCall/ -- Roche Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received 510(k) clearance from the U.S. Food ...
PLEASANTON, Calif., May 11, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the cobas® KRAS Mutation Test for ...
Studies showed that the assay demonstrated a 94.90% sensitivity in polymerase chain reaction-confirmed positive samples.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback